百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

交易中 12-08 11:14:56

193.500

-4.500

-2.27%

最高196.000	最低192.900	成交量180.93万
今开195.000	昨收198.000	日振幅1.57%
总市值2,982亿	流通市值2,759亿	总股本15.41亿
成交额3.51亿	换手率0.13%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":193.5,"timestamp":1765163692484,"preClose":198,"halted":0,"volume":1809262,"delay":0,"floatShares":1426000000,"shares":1541000000,"eps":-3.66537764256425,"marketStatus":"交易中","change":-4.5,"latestTime":"12-08 11:14:56","open":195,"high":196,"low":192.9,"amount":351349798,"amplitude":0.015657,"askPrice":193.5,"askSize":15100,"bidPrice":193.4,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.34996615339127457,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1765166400000},"marketStatusCode":2,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":198,"openAndCloseTimeList":[[1765157400000,1765166400000],[1765170000000,1765180800000]],"volumeRatio":1.789369,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":279.48,"timestamp":1765163688000,"preClose":279.25,"halted":0,"volume":1539100,"delay":0,"premium":"-37.11"}},"requestUrl":"/m/hq/s/06160/wiki","defaultTab":"wiki","newsList":[{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4599","LU1093756168.USD","02161","IE00BZ1G4Q59.USD","688235","BK4022","BK4532","NVO","02171","BK4007","BK4230","IE00BKVL7J92.USD","LU0154236417.USD","01228","ONC","02196","06160","LU1093756325.SGD"],"gpt_icon":0},{"id":"2589387525","title":"百济神州两款药品进入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589387525","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589387525?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:56","pubTimestamp":1765086982,"startTime":"0","endTime":"0","summary":"【百济神州两款药品进入2025年商保创新药目录】12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中，百济神州有两款药品成功纳入，包括达妥昔单抗β注射液以及注射用泽尼达妥单抗。百济神州也是唯一一家两款产品进入商保创新药目录的创新药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584561139.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584561139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4139","BK1588","06160","BK1500","BK1161","LU2328871848.SGD","06978","ONC","BK1574","LU1770034418.SGD","688235","LU1719994722.HKD","LU1969619763.USD","LU1303224171.USD","BK4585","LU0588546209.SGD","BK4526","LU0307460666.USD","159992","LU1251922891.USD","BK1583"],"gpt_icon":0},{"id":"2589369893","title":"创新药的叙事经济学：叙事即估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2589369893","media":"研究进化论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589369893?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:26","pubTimestamp":1764912419,"startTime":"0","endTime":"0","summary":"本文从叙事经济学角度来回答这些问题，谈谈估值和策略。这就是创新药估值的极大不确定性，在一个非常宽泛的范围里面波动。创新药行业也有很多叙事，而且由于管线关键节点之间的巨大信息真空期，提供给了叙事情绪很大的发挥空间，而不同的叙事会直接作用到上述DCF模型的各个因子上进而催动估值的大范围波动，对于这些叙事的跟踪和理解就成为了估值的一部分。特别是现在创新药行业大部分贡献估值的管线都还处在未成药的临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205135245a7253773&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205135245a7253773&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09926","06855","01276","LU2488822045.USD","09688","BK1161","06160","06978","BK1588"],"gpt_icon":0},{"id":"2589402852","title":"【券商聚焦】交银国际：医药行业短期催化剂充足 长期继续看好创新主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2589402852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589402852?lang=zh_cn&edition=full","pubTime":"2025-12-05 10:38","pubTimestamp":1764902337,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，2025年10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓从年中起亦呈回落态势，但内外资加大创新药布局的大方向不变。而外资则更积极，聚焦创新主线中的龙头及产业链上游，包括恒瑞医药、君实生物和荣昌生物等创新药，及康龙化成、药明康德和泰格医药等CXO标的。12月，行业仍有充足催化剂，包括各项学术大会、医保谈判结果公布、美联储潜在降息等，板块投资情绪有望稳中有升。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970976","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1303224171.USD","02268","BK1147","IE00BPRC5H50.USD","01789","BK1500","SG9999004311.SGD","01530","03933","BK1585","BK1141","LU0640798160.USD","BK1583","BK1197","BK1588","06160","LU1794554557.SGD","09926","LU1969619763.USD","LU0540923850.HKD","LU2488822045.USD","IE00B5MMRT66.SGD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","01099","SG9999014674.SGD","BK1617","02367","LU0348825331.USD","LU1770034418.SGD","02228","LU0348827113.USD","LU1251922891.USD","LU2328871848.SGD","LU2399975544.HKD","LU2476274308.USD","LU0417516571.SGD","03329","02196","09688","LU2778985437.USD","LU2476274720.SGD","BK1593","LU0348766576.USD","LU0417516902.SGD","HK0000165453.HKD","LU0588546209.SGD","LU0417516738.SGD"],"gpt_icon":1},{"id":"2588002521","title":"百济神州(06160)授出合共2.13万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002521?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","BK1588","BK4139","LU0307460666.USD","688235","LU0588546209.SGD","06160","LU1251922891.USD","BK4526","BK1583","LU2328871848.SGD","BK1500","BK4585","BK0239","LU1719994722.HKD","LU1969619763.USD","ONC","BK1161","LU1770034418.SGD"],"gpt_icon":0},{"id":"2588288888","title":"每日卖空追踪 | 百济神州 12月04日卖空量成交20.49万股，卖空比例为5.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588288888","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588288888?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837036,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月04日，涨1.88%，卖空量成交20.49万股，较上一交易日减少58.95%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163608978f88c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163608978f88c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1588","LU1719994722.HKD","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK1500","LU1303224171.USD","06160","LU2328871848.SGD","LU0588546209.SGD","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2588888477","title":"百济神州12月04日获主力加仓2337.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888477","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588888477?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:15","pubTimestamp":1764836113,"startTime":"0","endTime":"0","summary":"12月04日, 百济神州股价涨1.88%，报收200.40元，成交金额7.1亿元，换手率0.25%，振幅1.83%，量比1.12。百济神州今日主力资金净流入2337.2万元，上一交易日主力净流入1349.6万元。该股近5个交易日下跌0.98%，主力资金累计净流入9796.3万元；近20日主力资金累计净流入11.9亿元，其中净流入天数为18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161543a7234d32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161543a7234d32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","06160","LU1303224171.USD","LU1770034418.SGD","LU1969619763.USD","BK1161","BK1500","BK1588","BK1583","LU0588546209.SGD","LU1719994722.HKD","LU2328871848.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2588088829","title":"中泰证券：创新药行情有望持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088829","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588088829?lang=zh_cn&edition=full","pubTime":"2025-12-04 08:05","pubTimestamp":1764806725,"startTime":"0","endTime":"0","summary":"中泰证券研报表示，创新药仍是目前医药板块最重要的主线，且近2—3个月实现了震荡调整，股价位置、市场预期、资金配置等均回到了相对合理偏低的位置，投资安全边际及收益回报价值凸显。在创新药火热高涨及震荡回调中，医药板块内部均出现一定程度的高低切换或者主题轮动，因此同样建议积极布局2026年伴随价格出清、需求复苏、经营周期拐点有望出现基本面改善的板块及个股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204080545a722679d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204080545a722679d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU1770034418.SGD","BK1583","BK1500","LU1719994722.HKD","LU2328871848.SGD","BK1161","LU0307460666.USD","BK1588","LU1251922891.USD","LU1969619763.USD","BK1574","LU1303224171.USD","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2588048711","title":"决胜港股升浪・致敬卓越力量，“第十届智通财经资本市场年会暨上市公司颁奖盛典”25项大奖揭晓!","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588048711?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:21","pubTimestamp":1764760876,"startTime":"0","endTime":"0","summary":"2025年12月3日，由国内领先的港美股资讯平台智通财经与中资海外私募基金一站式服务平台新智基金网联合主办、财经公关综合服务提供商冬日暖阳 Donova 独家承办的 “第十届智通财经资本市场年会暨上市公司颁奖盛典” 在深圳盛大启幕。荣耀加冕：231 家企业及管理者斩获 25 项年度大奖当晚的颁奖典礼星光熠熠，各项大奖实至名归。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","09699","02556","00017","02498","00363","00875","02256","00460","00135","00777","00861","00960","00136","00656","02419","00267","00992","02511","02525","00305","00384","00699","00020","02121","00382","00867","06160","02142","00999","00826","00300","01070","01833","02105","02279","00512","00003","02380","09678","00302","00855","00666","00451","00798","00884","01093","09878"],"gpt_icon":1},{"id":"2588003899","title":"12月3日港股药品及生物科技行业沽空数据盘点，三生制药、信达生物、百济神州沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2588003899","media":"证券之星APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588003899?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:06","pubTimestamp":1764756374,"startTime":"0","endTime":"0","summary":"当日药品及生物科技行业总体跌1.74%。从沽空金额来看，三生制药、信达生物、百济神州沽空金额位居行业前三，分别为2.37亿港元、1.53亿港元、9825.69万港元。从沽空比例偏离度来看，乐普生物-B、思派健康、信达生物沽空比例偏离度位居行业前三，分别为306.25%、195.17%、192.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120318154995289c94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120318154995289c94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU2242644610.SGD","HK0000165453.HKD","BK1588","01530","LU2097828714.EUR","LU0502904849.HKD","LU2097828631.EUR","BK1589","LU1719994722.HKD","LU2097828557.USD","BK1583","BK1500","LU2097828474.EUR","LU1251922891.USD","01801","LU0307460666.USD","BK1161","LU1770034418.SGD","06160","LU2328871848.SGD","LU1303224171.USD","LU0588546209.SGD","LU0455707207.USD","BK1593"],"gpt_icon":0},{"id":"2588343016","title":"创新药概念持续调整 歌礼制药(01672)跌逾1成 机构指仿制药下降趋势无法避免 影响制药行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588343016","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588343016?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:08","pubTimestamp":1764749332,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念持续调整，临近收盘，歌礼制药(01672)跌11.1%，圣诺医药(02257)跌10.9%，信达生物(01801)跌2.72%，药明生物(02269)跌1.8%，百济神州(06160)跌1.35%。国元国际指出，医药行业目前已经进行了十一批国家药品集中带量采购以及多轮医保谈判，随着药品带量采购的常态化进行，仿制药行业的下降趋势无法避免，对制药行业有一定的影响。2025年1-9月医药制造业实现营业收入同比略下降2.0%，利润总额同比略下降0.7%，整体比较平稳。受集采、医保谈判的影响，仿制药的前景平淡，未来行业的发展需要创新药来推动增长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970832","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1688375341.USD","LU2097828805.USD","LU0327786744.USD","LU0140636845.USD","LU2097828714.EUR","LU1794554557.SGD","LU2488822045.USD","LU0979878070.USD","LU0052750758.USD","159992","LU1242518857.USD","LU1720050803.USD","LU1770034418.SGD","BK1161","LU0588546209.SGD","02257","LU0516422440.USD","LU3063872942.SGD","LU0819121731.USD","06160","06978","LU1242518931.SGD","02269","LU1303224171.USD","01801","BK1576","LU0455707207.USD","LU0516422952.EUR","LU0417516738.SGD","SG9999002562.SGD","BK1610","LU0181495838.USD","LU0051755006.USD","BK1141","LU0039217434.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU2097828631.EUR","LU2097828474.EUR","LU2039709279.SGD","BK1521","LU0417516902.SGD","LU0502904849.HKD","01477","LU1880383366.USD","HK0000165453.HKD","01672","LU0307460666.USD","BK1191"],"gpt_icon":0},{"id":"2588033857","title":"凌科药业递表港股IPO，上轮投后估值34.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588033857","media":"医药笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588033857?lang=zh_cn&edition=full","pubTime":"2025-12-01 18:19","pubTimestamp":1764584347,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年11月30日，凌科药业港股IPO申请获得受理，招股书正式公开。凌科药业成立于2017年，聚焦研发自身免疫及炎症性疾病的差异化小分子创新药，首发管线为高选择性JAK1抑制剂LNK01011，后续管线还有泛JAK抑制剂LNK01004、透脑TYK2抑制剂LNK01006、系统性TYK2抑制剂LNK01007等。截至2025年三季度末，凌科药业账上现金为1.47亿元。2023年，凌科药业通过两期完成C轮融资合计3.22亿元，投前估值31亿元，投后估值34.22亿元。凌科药业最新股权结构如下表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201232204a4c61570&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201232204a4c61570&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1251922891.USD","BK1500","LU2328871848.SGD","BK1588","LU0588546209.SGD","LU0307460666.USD","LU1719994722.HKD","LU1969619763.USD","BK1161","06160","LU1303224171.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2588477723","title":"每日卖空追踪 | 百济神州 12月01日卖空量成交17.65万股，卖空比例为6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588477723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588477723?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577835,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月01日，跌0.59%，卖空量成交17.65万股，较上一交易日减少59.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011635339789567d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011635339789567d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1251922891.USD","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","BK1583","BK1588","BK1500","BK1161","LU0588546209.SGD","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2588777237","title":"医药行业周报：医药板块有所反弹，建议关注低位个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777237","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588777237?lang=zh_cn&edition=full","pubTime":"2025-12-01 12:08","pubTimestamp":1764562080,"startTime":"0","endTime":"0","summary":"投资要点行情回顾：本周医药生物指数上涨2.67%，跑赢沪深300指数1.03个百分点，行业涨跌幅排名第17。器械板块迎利好，北京、上海接连发文支持医疗器械发展。此外《若干措施》缩短了多项医药板块审评速度，包括部分新药入院流程从30个工作日压缩至15个工作日，第二类医疗器械首次注册周期压缩至6个月，流感疫苗批签发时限缩至30个工作日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011208189523dfcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011208189523dfcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1251922891.USD","LU2328871848.SGD","LU1303224171.USD","BK1583","LU1969619763.USD","BK1500","BK1515","BK1574","LU0307460666.USD","09939","BK1588","LU1770034418.SGD","LU1719994722.HKD","06160","BK1161"],"gpt_icon":0},{"id":"2588431377","title":"港股医药投资迎新篇章！恒生生物科技ETF富国今日盛大首发！","url":"https://stock-news.laohu8.com/highlight/detail?id=2588431377","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588431377?lang=zh_cn&edition=full","pubTime":"2025-12-01 11:04","pubTimestamp":1764558240,"startTime":"0","endTime":"0","summary":"近期，医药生物板块利好密集释放。与此同时，港股医药投资生态亦迎重磅升级——恒生生物科技指数期货已于11月28日正式上市交易。在此双重利好驱动下，富国基金顺势推出恒生生物科技ETF富国，该基金于今日重磅首发，为投资者提供了高效布局港股生物科技龙头的前沿工具。恒生生物科技ETF富国凭借其对核心资产的精准覆盖、科学的指数编制与显著的估值优势，为投资者提供了把握产业变革机遇的高效工具。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201110535a71bd9cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201110535a71bd9cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","LU1969619763.USD","LU2242644610.SGD","01801","06160","LU2097828631.EUR","LU2097828474.EUR","BK1574","BK1583","LU2097828805.USD","LU2488822045.USD","HK0000165453.HKD","BK1589","02269","LU2097828557.USD","LU0455707207.USD","BK1161","06978","LU0502904849.HKD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2587973017","title":"智通财经港股12月投资策略及十大金股","url":"https://stock-news.laohu8.com/highlight/detail?id=2587973017","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587973017?lang=zh_cn&edition=full","pubTime":"2025-11-30 22:19","pubTimestamp":1764512382,"startTime":"0","endTime":"0","summary":"随后“鲍威尔盟友”连续发声支持降息，市场对美联储 12 月降息预期大幅升至 80%。2025 年 12 月投资策略：跟着预期走智通财经 11 月金股持续跑赢大盘。11 月同期恒指最大涨幅 5%，十大金股 11 月平均最大涨幅 11.6%。其次是 12 月一些重大事件带来的预期。大的事件层面，机器人消息比较多，宇树科技：预计 12 月底前提交 IPO 申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0499858602.USD","LU0348766576.USD","BK4123","LU0211977185.USD","BK1161","159934","BK1529","DUST","09863","03692","BK1133","LU0327786744.USD","06160","02238","BK1148","02282","IAU","00552","BK1172","02648","518880","00788","BK1198","GCmain","LU0499858438.USD","BK1183","SGCmain","LU0823413660.USD","GDX","LU0164865239.USD","LU1481107354.HKD","BK1521","NUGT","MG","LU0345776255.USD","LU0823413587.USD","SGUmain","SGXZ86797644.SGD","LU0593848301.USD","02099","02402","LU0039217434.USD","09995","BK1191","MGCmain","SGXZ62798434.SGD","02465"],"gpt_icon":1},{"id":"2586724564","title":"百济神州BCL2抑制剂“索托克拉”在美国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724564","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586724564?lang=zh_cn&edition=full","pubTime":"2025-11-27 14:59","pubTimestamp":1764226799,"startTime":"0","endTime":"0","summary":"11月26日，百济神州宣布FDA已受理新一代BCL2抑制剂索托克拉的新药上市申请，并授予优先审评资格，拟用于治疗接受过布鲁顿氏酪氨酸激酶抑制剂治疗的复发或难治性（R/R）套细胞淋巴瘤患者。实验室和早期药物开发研究结果表明，索托克拉是一种具有强效性和特异性的BCL2抑制剂，半衰期短且无蓄积。此外，索托克拉的耐受性良好，风险可控。MCL约占全球所有NHL病例5%，大约28,000例患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127151721a714a591&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127151721a714a591&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU2328871848.SGD","LU1719994722.HKD","BK1500","06160","BK1588","LU0307460666.USD","LU0588546209.SGD","LU1770034418.SGD","LU1969619763.USD","LU1303224171.USD","BK1583","BK1161"],"gpt_icon":1},{"id":"2586260666","title":"研报点睛：涨幅居前！关注这一赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260666","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586260666?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:35","pubTimestamp":1764149725,"startTime":"0","endTime":"0","summary":"11月26日，A股三大指数今日涨跌不一，截止收盘，沪指跌0.15%，收报3864.18点；深证成指涨1.02%，收报12907.83点；创业板指涨2.14%，收报3044.69点。国金证券表示，CGT 等前沿创新，或迎监管更多支持；数据生态新赛道，隐藏未来新金矿。颠覆性创新技术赛道的布局，将是未来药企制胜要地。新一代技术的细胞基因疗法、AI制药等前沿赛道，或是2026年新热点。医药医疗数据要素相关企业，值得药企布局和资本市场关注与投资。国泰海通表示，持续推荐创新药械及产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","06990","LU0359202008.SGD","LU0359201612.USD","06160","01276","BK1191","LU1023057109.AUD","02359","LU0359201885.HKD","02615","03347"],"gpt_icon":0},{"id":"2586219500","title":"每日卖空追踪 | 百济神州 11月26日卖空量成交58.4万股，卖空比例为13.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219500?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145832,"startTime":"0","endTime":"0","summary":"百济神州北京时间11月26日，涨0.2%，卖空量成交58.4万股，较上一交易日减少38.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163536951b4c2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163536951b4c2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","LU1969619763.USD","BK1583","06160","LU1251922891.USD","LU1770034418.SGD","BK1500","LU0307460666.USD","LU0588546209.SGD","BK1161","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"2586219658","title":"百济神州11月26日获主力加仓7495.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219658","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219658?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:15","pubTimestamp":1764144952,"startTime":"0","endTime":"0","summary":"11月26日, 百济神州股价涨0.20%，报收205.20元，成交金额8.9亿元，换手率0.30%，振幅2.73%，量比1.07。百济神州今日主力资金净流入7495.4万元，连续5日净流入，上一交易日主力净流入5660.3万元。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为36.36%，平均涨幅为2.47%。该股近5个交易日下跌4.92%，主力资金累计净流入2.1亿元；近20日主力资金累计净流入10.9亿元，其中净流入天数为18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126162113a4bb5754&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126162113a4bb5754&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","LU2328871848.SGD","BK1161","LU1251922891.USD","BK1583","LU0307460666.USD","BK1500","LU1719994722.HKD","LU0588546209.SGD","BK1588","LU1770034418.SGD","06160","LU1969619763.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0332},{"period":"1month","weight":0.0668},{"period":"3month","weight":-0.0198},{"period":"6month","weight":0.2684},{"period":"1year","weight":0.631},{"period":"ytd","weight":0.8132}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.064356}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}